Rhythm Pharmaceuticals, Inc. (RYTM)
112.36
-4.44
(-3.80%)
USD |
NASDAQ |
Nov 20, 16:00
113.50
+1.14
(+1.01%)
After-Hours: 20:00
Rhythm Pharmaceuticals Research and Development Expense (TTM) : 179.52M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 179.52M |
| June 30, 2026 | 173.01M |
| March 31, 2026 | 171.76M |
| December 31, 2025 | 166.89M |
| September 30, 2025 | 165.86M |
| June 30, 2025 | 157.69M |
| March 31, 2025 | 145.58M |
| December 31, 2024 | 237.25M |
| September 30, 2024 | 225.94M |
| June 30, 2024 | 221.52M |
| March 31, 2024 | 224.82M |
| December 31, 2023 | 134.05M |
| September 30, 2023 | 127.68M |
| June 30, 2023 | 115.22M |
| March 31, 2023 | 113.14M |
| December 31, 2022 | 107.73M |
| September 30, 2022 | 115.78M |
| June 30, 2022 | 122.22M |
| March 31, 2022 | 115.89M |
| December 31, 2021 | 103.31M |
| September 30, 2021 | 93.72M |
| June 30, 2021 | 89.38M |
| March 31, 2021 | 87.48M |
| December 31, 2020 | 90.27M |
| Date | Value |
|---|---|
| September 30, 2020 | 93.31M |
| June 30, 2020 | 96.88M |
| March 31, 2020 | 109.19M |
| December 31, 2019 | 109.45M |
| September 30, 2019 | 103.40M |
| June 30, 2019 | 87.54M |
| March 31, 2019 | 60.81M |
| December 31, 2018 | 50.34M |
| September 30, 2018 | 38.23M |
| June 30, 2018 | 33.49M |
| March 31, 2018 | 30.31M |
| December 31, 2017 | 22.89M |
| September 30, 2017 | 21.66M |
| June 30, 2017 | 20.31M |
| March 31, 2017 | 18.84M |
| September 30, 2016 | 17.58M |
| June 30, 2016 | 14.36M |
| March 31, 2016 | 10.35M |
| December 31, 2015 | |
| September 30, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | 14.55M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.559B |
| Arrowhead Pharmaceuticals, Inc. | 929.60M |
| BioMarin Pharmaceutical, Inc. | 758.69M |
| Cytokinetics, Inc. | 383.50M |
| Exelixis, Inc. | 834.63M |